Cargando…

Indirect Comparison Showed Survival Benefit from Adjuvant Chemoradiotherapy in Completely Resected Gastric Cancer with D2 Lymphadenectomy

Background. Little data on directly comparing chemoradiotherapy with observation has yet been published in the setting of adjuvant therapy for resected gastric cancer who underwent D2 lymphadenectomy. The present indirect comparison aims to provide more evidence on comparing the two approaches. Meth...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Qiong, Wei, Ying, Chen, Yan-Xian, Zhou, Si-Wei, Jiang, Zhi-Min, Xie, De-Rong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2013
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3806404/ https://www.ncbi.nlm.nih.gov/pubmed/24194750 http://dx.doi.org/10.1155/2013/634929

Ejemplares similares

Postoperative Chemoradiotherapy versus Postoperative Chemotherapy for Completely Resected Gastric Cancer with D2 Lymphadenectomy: A Meta-Analysis
por: Huang, Yuan-Yuan, et al.
Publicado: (2013)

Correction: Postoperative Chemoradiotherapy versus Postoperative Chemotherapy for Completely Resected Gastric Cancer with D2 Lymphadenectomy: A Meta-Analysis
por: Huang, Yuan-Yuan, et al.
Publicado: (2013)

Effect of adjuvant chemoradiotherapy on overall survival of gastric cancer patients submitted to D2 lymphadenectomy
por: Jácome, Alexandre A. A., et al.
Publicado: (2012)

A phase II trial of post-operative chemoradiotherapy for completely resected gastric cancer with D2 lymphadenectomy
por: ZHAI, YU-JIE, et al.
Publicado: (2014)

Benefit of Adjuvant Chemoradiotherapy in Resected Gallbladder Carcinoma
por: Kim, Tae Hyun, et al.
Publicado: (2019)

D2‐resected stage IIIc gastric cancer patients benefit from adjuvant chemoradiotherapy
por: Peng, Jin, et al.
Publicado: (2016)

Survival Benefit of Adjuvant Radiation Therapy for Gastric Cancer following Gastrectomy and Extended Lymphadenectomy
por: Snyder, R. A., et al.
Publicado: (2012)

Survival Benefit and Safety of No. 10 Lymphadenectomy for Gastric Cancer Patients With Total Gastrectomy
por: Yang, Kun, et al.
Publicado: (2014)

Rectal cancer patients with downstaging after neoadjuvant chemoradiotherapy and radical resection do not benefit from adjuvant chemotherapy
por: Zhang, Hang, et al.
Publicado: (2020)

Individualized prediction of survival benefits from perioperative chemoradiotherapy for patients with resectable gastric cancer
por: Che, Keying, et al.
Publicado: (2020)

Benefit of adjuvant chemoradiotherapy in patients with pathological stage III gastric cancer
por: Ma, Gui-Fen, et al.
Publicado: (2019)

Time-related improvement of survival in resectable gastric cancer: the role of Japanese-style gastrectomy with D2 lymphadenectomy and adjuvant chemotherapy
por: Grau, Juan J, et al.
Publicado: (2006)

Adjuvant chemoradiotherapy after d2-lymphadenectomy for gastric cancer: the role of n-ratio in patient selection. results of a single cancer center
por: Costa, Wilson L, et al.
Publicado: (2012)

The survival benefit and safety of No. 12a lymphadenectomy for gastric cancer patients with distal or total gastrectomy
por: Yang, Kun, et al.
Publicado: (2016)

Development and Validation of a Nomogram to Predict the Benefit of Adjuvant Radiotherapy for Patients with Resected Gastric Cancer
por: Yuan, Shu-Qiang, et al.
Publicado: (2017)

Assessment of quality of life in resectable gastric cancer patients undergoing chemoradiotherapy as adjuvant treatment
por: Pruthi, Deep Shankar, et al.
Publicado: (2018)

Survival benefit of No. 10 lymphadenectomy with spleen preservation
por: Song, Jeong Ho, et al.
Publicado: (2022)

Postoperative Adjuvant Chemoradiotherapy on the Survival of Stage III Gastric Cancer
por: Li, Chao, et al.
Publicado: (2022)

The Efficacy of Adjuvant FOLFOX6 for Patients With Gastric Cancer after D2 Lymphadenectomy: A Propensity Score-matched Analysis
por: Wang, Zi-Xian, et al.
Publicado: (2016)

Individualized pelvic lymphadenectomy should follow neoadjuvant concurrent chemoradiotherapy for locally advanced cervical cancer
por: Wei, Li-Chun, et al.
Publicado: (2018)

Chemoradiotherapy or chemotherapy as adjuvant treatment for resected gastric cancer: should we use selection criteria?
por: Mansouri, Houyem, et al.
Publicado: (2021)

Association between adjuvant chemotherapy and survival in patients with rectal cancer and pathological complete response after neoadjuvant chemoradiotherapy and resection
por: He, Fang, et al.
Publicado: (2020)

Retracted: Postoperative Adjuvant Chemoradiotherapy on the Survival of Stage III Gastric Cancer
por: Methods in Medicine, Computational and Mathematical
Publicado: (2023)

Significant survival benefit of adjuvant chemotherapy after concurrent chemoradiotherapy in locally advanced high-risk nasopharyngeal carcinoma
por: Liang, Zhong-Guo, et al.
Publicado: (2017)

Preoperative Splenic Density for the Prediction of Survival and Adjuvant Chemotherapy Benefits in Gastric Cancer
por: Zhang, Wei-teng, et al.
Publicado: (2020)

Benefit of Adjuvant Traditional Herbal Medicine With Chemotherapy for Resectable Gastric Cancer
por: Lee, Yu Kyung, et al.
Publicado: (2018)

Lymphadenectomy and adjuvant therapy in endometrial carcinoma: role of adjuvant chemotherapy
por: Otsuka, I, et al.
Publicado: (2002)

Neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy for patients with resectable gastric cancer (CRITICS)
por: Dikken, Johan L, et al.
Publicado: (2011)

Adjuvant Chemoradiotherapy Versus Adjuvant Chemotherapy for Stage III Gastric or Gastroesophageal Junction Cancer After D2/R0 Resection
por: Shi, Jinming, et al.
Publicado: (2022)

Identification of Patients With Locally Advanced Gastric Cancer Who May Benefit From Adjuvant Chemoradiotherapy After D2 dissection: A Propensity Score Matching Analysis
por: Wang, Shu-Bei, et al.
Publicado: (2021)

Efficacy of Neo-Adjuvant Chemoradiotherapy for Resectable Pancreatic Adenocarcinoma: A PRISMA-Compliant Meta-Analysis and Systematic Review
por: Liu, Wei, et al.
Publicado: (2016)

Survival benefits of pelvic lymphadenectomy versus pelvic and para-aortic lymphadenectomy in patients with endometrial cancer: A meta-analysis
por: Guo, Weina, et al.
Publicado: (2018)

Adjuvant chemoradiotherapy in resected gallbladder cancer: A SEER-based study
por: Jiang, Yong, et al.
Publicado: (2023)

Adjuvant Chemoradiotherapy for Gastric Cancer: Efficacy and Cost-Effectiveness Analysis
por: Zhang, Mengxi, et al.
Publicado: (2019)

Immune Score Predicts Outcomes of Gastric Cancer Patients Treated with Adjuvant Chemoradiotherapy
por: Zou, Wei, et al.
Publicado: (2021)

Adjuvant chemoradiotherapy for patients with pathologic node-positive esophageal cancer following radical resection is associated with improved survival
por: Zheng, Bin, et al.
Publicado: (2020)

Therapeutic Benefit of Systematic Lymphadenectomy in Node-Negative Uterine-Confined Endometrioid Endometrial Carcinoma: Omission of Adjuvant Therapy
por: Otsuka, Isao
Publicado: (2022)

Metachronous metastasis- and survival-analysis show prognostic importance of lymphadenectomy for colon carcinomas
por: Laubert, Tilman, et al.
Publicado: (2012)

Oncologic Benefit of Adjuvant Therapy in Lateral Pelvic Lymph Node Metastasis following Neoadjuvant Chemoradiotherapy and Lateral Pelvic Lymph Node Dissection
por: Jiang, Yu-Juan, et al.
Publicado: (2022)

The watch-and-wait strategy versus surgical resection for rectal cancer patients with a clinical complete response after neoadjuvant chemoradiotherapy
por: Wang, Qiao-xuan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_uhclnb9rsbhr96q5h00dbfkhjk